MLTX
MoonLake Immunotherapeutics·Healthcare
18.41
0.987%(+0.18)
Close PriceLast Updated: — ET
52W L: $5.9552W H: $62.75
MLTX NEWS
benzinga.com
May 11
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars
MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up during Monday's trading session, trading higher as the company is reporting positive outcomes from its final pre-BLA meeting with the FDA regarding its sonelokimab (SLK) program for hidradenitis suppurativa (HS).
investors.com
May 11
MoonLake Clears A Key Regulatory Hurdle, And Shares Rocket
Shares of MoonLake Immunotherapeutics bounded higher Monday after the biotech said it met with the Food and Drug Administration in April.
globenewswire.com
May 10
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced a positive outcome of its final pre-BLA meeting held on April 1, 2026, with the FDA on the HS program of its Nanobody® SLK.
fool.com
Apr 18
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock?
CEO Jorge Santos da Silva sold 150,000 shares for a transaction value of approximately ~$2.75 million, based on a weighted average sale price of $18.35 per share. The sale represented 4.9% of Mr.
defenseworld.net
Apr 16
Da Silva Jorge Santos Sells 98,127 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report) CEO Da Silva Jorge Santos sold 98,127 shares of the firm's stock in a transaction on Friday, April 10th. The shares were sold at an average price of $18.41, for a total transaction of $1,806,518.07. Following the completion of the transaction, the chief executive officer directly owned 2,976,766
defenseworld.net
Apr 12
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6% – Should You Sell?
MoonLake Immunotherapeutics (NASDAQ: MLTX - Get Free Report)'s share price traded down 6% during mid-day trading on Friday. The company traded as low as $18.36 and last traded at $18.2540. 326,345 shares were traded during trading, a decline of 83% from the average session volume of 1,947,956 shares. The stock had previously closed at $19.41.
